Granted, the authors only studied 890 volunteers, average age at death 81yo, 43% female, almost all Caucasian. As noted in yesterday's study on spin, that makes the results of this study less generalizable to a more ethnically diverse population. Moreover, this study was performed upon death so to some extent, it's useless for the living. In fact, they only looked for neuropathological evidence of Alzheimer's disease but there was no mention of clinically relevant outcomes, eg cognition & function. On the other hand, it wouldn't be so difficult to consider an ARB in treating someone w/hypertension who is deathly afraid of dementia (not that we all aren't). But I think we're jumping the gun since we have no trials demonstrating clinical benefit.
Or do we? A prospective cohort analysis published January 2010 in BMJ of 819, 491 men older than 65yo w/heart disease followed for 4yrs concluded that ARBs are associated with significant reduction in Alzheimer's disease, both incidence & progression, when compared to ACE inhibitors! In a small short randomized controlled trial published May 2008 in Neurology of the ARB, candesartan, vs placebo, 257 participants, average 76yo were randomized to candesartan vs placebo. After 44 months, the authors concluded that use of candesartan was associated with less decline in attention & episodic memory. Unfortunately, we can't conclude from this particular study whether any anti-hypertensive would have achieved the same effect . . .
But certainly the trend is there. I guess I'll have to reconsider using ARBs in my hypertensive patients who value preventing dementia over all-cause mortality.
Tweet
No comments:
Post a Comment